Delving into the Latest Updates on Nivolumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Nivolumab (Genetical Recombination), Nivolumab (genetical recombination) (JAN), Nivolumab (USAN/INN)

+ [16]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [13]

Active Indication

Microsatellite instability-high Rectal CancerPD-L1 positive Non-Small Cell Lung CancerMetastatic hepatocellular carcinoma+ [503]

Inactive Indication

Acidemia, IsovalericAcquired Immunodeficiency SyndromeAcute lymphoblastic leukemia recurrent+ [111]

Originator Organization

Ono Pharmaceutical Co., Ltd.

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

The University of Texas MD Anderson Cancer Center

National Cancer Institute

+ [28]

Inactive Organization

Nektar Therapeutics

Regeneron Pharmaceuticals, Inc.

Vedanta Biosciences, Inc.

+ [14]

License Organization

Nektar Therapeutics

NeoImmuneTech, Inc.

Vedanta Biosciences, Inc.

+ [19]

Drug Highest PhaseApproved

First Approval Date

Japan (04 Jul 2014),

Esophageal CarcinomaMelanoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Priority Review (Australia), Conditional marketing approval (China), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Sequence Code 93681H

Source: *****

Sequence Code 93684L

Source: *****

In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. In our work, we deeply analyzed the results of the three pivotal studies in view of the rapidly evolving therapeutic advanced UC's scenario. Furthermore, there are several ongoing research to investigate ICIs and other emerging immune agents in this setting; results are awaited. Additionally, current efforts have been made to assess the role of these agents in earlier disease settings, particularly in high-risk non-muscle-invasive bladder cancer (NMIBC). In our review, we analyzed the potential role of predictive and/or prognostic biomarkers that may improve patient selection and treatment efficacy. To conclude, we highlighted the upcoming changes that could redefine the standard of care for patients with early-stage UC.

2,046

News (Medical) associated with Nivolumab

12 hours ago

·www.prnewswire.com

Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 40th Anniversary Annual Meeting

MILWAUKEE, Oct. 30, 2025 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to announce the titles and authors for the clinical Late-breaking Abstracts (LBA) . The abstracts will be presented at SITC's upcoming 40th Anniversary Annual Meeting & Pre-Conference Programs taking place Nov. 5–9, 2025, in National Harbor, MD and virtually. Continue Reading SITC 2025 Logo "We are excited to incorporate these clinical abstracts into an already impressive lineup of abstracts that will be presented at SITC. The Late-breaking Abstracts this year will only focus on late-breaking data from interventional clinical trials in humans and will further enhance the cutting-edge science offered at the 40th Anniversary Annual Meeting," said SITC Vice President Sandra Demaria MD. "SITC is committed to accelerating the approval of 100 novel agents by 2034, and providing a platform to showcase the latest clinical advancements at our Annual Meeting is an important component of this goal." The Late-breaking Abstracts with oral presentations at the 40th Anniversary Annual Meeting are: (1316) Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a Phase 1/2 trial Aurélien Marabelle, MD, PhD – Gustave Roussy & Paris Saclay University Session 104: Clinical Oral Abstract Session – Friday, Nov. 7, 2025 – 11:30 a.m. ET (1342) First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 in vivo CAR therapy in solid tumors Rasha Cosman, BSc (Med), MBBS, FRACP – St. Vincent's Hospital Session 104: Clinical Oral Abstract Session – Friday, Nov. 7, 2025 – 11:30 a.m. ET (1348) Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment Li Zhang, MD – Sun Yat-Sen University Cancer Center Session 104: Clinical Oral Abstract Session – Friday, Nov. 7, 2025 – 11:30 a.m. ET (1305) Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): results from cohort A of the phase 2 KeyForm-010 study Matteo Carlino, MBBS, PhD, BMedSC, FRACP – The University of Sydney Session 106a: Considerations for Incorporating Biomarkers in Perioperative/Neoadjuvant Therapy – Friday, Nov. 7, 2025 – 1:45 p.m. ET (1346) Molecular and immunologic correlates of response in a phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma Kenneth Tsai, MD, PhD – Moffitt Cancer Center Session 106a: Considerations for Incorporating Biomarkers in Perioperative/Neoadjuvant Therapy – Friday, Nov. 7, 2025 – 1:45 p.m. ET (1327) Biomarker and updated clinical data for RP1 plus nivolumab in anti-PD-1-failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade Trisha Wise-Draper, MD, PhD– University of Cincinnati Cancer Center Session 107d: The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics – Friday, Nov. 7, 2025 – 3:55 p.m. ET (1328) SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC): results from a phase 2 study Lin Wu, PhD –Hunan Cancer Hospital Session 107d: The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics – Friday, Nov. 7, 2025 – 3:55 p.m. ET (1310) A phase 1/IIa study of ILKN421H, a LNP mRNA encoding an IL2Rβγ selective IL-2v, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors Haining Huang, PhD- ILeukon Therapeutics Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET (1325) SCOPE, an open label phase 2 parallel multi cohort clinical trial evaluating an off-the-shelf DNA plasmid vaccine in first line advanced melanoma combined with check point blockade - interim read-out Nermeen Varawalla, MD, PhD, MBA – Scancell Ltd Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET (1336) Final ph1b/2 results for Nous-209 monotherapy in Lynch syndrome carriers: Annual revaccination boosts T cell immunity informing future cancer interception strategies Anna Morena D'Alise, PhD – Nouscom SRL Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET (1340) Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma Lilit Karapetyan, MD – Moffitt Cancer Center Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET (1345) Initial phase 1a/1b results of STK-012, an α/β IL-2 receptor biased partial agonist, with pembrolizumab, pemetrexed, and carboplatin in 1L PD-L1 negative non-squamous NSCLC Adam Schoenfeld, MD – Memorial Sloan-Kettering Cancer Center Session 206: Clinical Oral Abstract Session – Saturday, Nov. 8, 2025 – 1:45 p.m. ET The full Regular and Young Investigator Award abstracts will be available on Nov. 4 at 9 a.m. ET and LBA – Clinical Only abstracts will be made available on Nov. 7 at 9 a.m. ET. Both types of abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC) Clinical Late-breaking Abstract Sessions with oral abstract presentations will take place on Friday, Nov. 7 from 11:30 a.m.–12:15 p.m. CT and Saturday, Nov. 8 from 1:45–3 p.m. ET in the Gaylord National Resort and Convention Center - Ballroom Level - Potomac Ballroom. In addition, Late-breaking Abstract posters will be presented in the Exhibit and Poster Hall and the virtual ePoster Hall beginning Friday, Nov. 7 at 10 a.m. ET. To learn more about the Late-breaking Abstracts, visit the 40th Annual Meeting & Pre-Conference Programs website. To register for the 40th Anniversary Annual Meeting and Pre-Conference Programs, click here. About SITC The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit and follow us on X, LinkedIn, Facebook and YouTube. SOURCE Society for Immunotherapy of Cancer (SITC) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Clinical ResultImmunotherapyVaccine

30 Oct 2025

·www.biospace.com

BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates

iStock, JHVEPhoto Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives on the company’s investor call faced questions about a sluggish uptake for schizophrenia drug Cobenfy as well as a highly anticipated Alzheimer’s psychosis readout for the product. Bristol Myers Squibb exceeded analyst expectations for third quarter earnings, driven largely by its growth portfolio, but all eyes were on recently approved schizophrenia drug Cobenfy, which came in slightly below estimates. On the company’s Q3 call on Thursday, BMS executives emphasized challenges in breaking into the market with a new mechanism—Cobenfy was approved by the FDA in September 2024 as the first novel drug for schizophrenia in 35 years. In its presentation, BMS said the continued focus will be on changing the “deeply ingrained D2 [dopamine] prescribing habits through education.” Cobenfy brought in $43 million for the quarter, falling below William Blair’s estimate of $46 million and consensus estimate of $45 million, according to a Thursday morning note from the firm. The drug has brought in $105 million to date, BMS CFO David Elkins said on the call. Despite this, CEO Chris Boerner struck an optimistic tone. “Cobenfy is delivering steady growth as we continue to receive positive feedback from physicians on key indicators, supporting our expectation that this is a meaningful first indication for Cobenfy,” he said. Beyond schizophrenia, BMS is studying Cobenfy in Alzheimer’s disease—the drug’s initial target in early development—and analysts had speculated that a readout for the Phase III ADEPT-2 trial, which pits Cobenfy against placebo in treating patients with moderate to severe psychosis attributed to the disease, would arrive Thursday along with the Q3 results. “We await updates on the delayed Cobenfy ADEPT-2 Alzheimer’s Disease Psychosis (ADP) trial, which management is scrutinizing due to concerns about trial execution,” Leerink wrote in a note to investors Thursday morning. In June, Leerink analysts said that Alzheimer’s patients are more sensitive to side effects in the digestive system, Fierce Pharma reported at the time. Two other studies of Cobenfy in Alzheimer’s—ADEPT-4 and ADEPT-1 in Alzheimer’s disease psychosis—are expected to read out next year. “We anticipate needing two of these three studies to read out positively to support regulatory approval,” Boerner said. Boerner emphasized that BMS is “entering a data-rich period,” with the pace of pivotal readouts accelerating in 2026. The CEO specifically highlighted readouts for admilparant in idiopathic pulmonary fibrosis, mezigdomide in multiple myeloma and Sotyktu in Sjögren’s disease. Overall, BMS’ growth portfolio performed well, thanks to strong sales from cancer blockbuster Opdivo ($2.5 billion), CAR T therapy Breyanzi ($359 million, up 58% year over year) and Camzyos ($296 million, an increase of 88%), leading to a total of $6.9 billion in revenue for the quarter. This made up more than half of BMS’ total Q3 revenue of $12.2 billion. BMS raised its full year 2025 revenue guidance from $46.5 billion to $47.5 billion to a new range of $47.5 billion to $48 billion. ‘Constructive’ Conversations on MFN As with its peers this earnings season, BMS also faced questions on drug pricing—specifically whether the company is in the process of negotiating an agreement with the White House. “We continue to actively engage with the administration,” Boerner said in response to an analyst’s question. “I would characterize those discussions as frequent, and while not always fully aligned, they’re always constructive and thought provoking on both sides.” “We agree with the president on the need for equalization of prices,” Boerner continued, echoing peers who have said the same in recent days, including Novartis CEO Vas Narasimhan . “U.S. prices need to come down. We’re sharing ideas to do that. We’ve seen some good progress, for example, in the U.K., but more needs to be done in accomplishing those objectives while preserving the ecosystem for innovation that we have in the U.S.” While Boerner said that Most Favored Nation drug pricing and tariffs are “always front and center,” BMS continues to monitor a host of other issues, including the current federal government shutdown and what potential impact that could have downstream.

Drug ApprovalPhase 3

28 Oct 2025

·www.prnewswire.com

Global Initiative to Demonstrate Operational Excellence in Nigeria for Metastatic Colorectal Cancer Patients

ABUJA, Nigeria, Oct. 28, 2025 /PRNewswire/ -- Today, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide an immunotherapy drug used to treat cancer. The goal of the initiative is to develop an approach that explores sustainable and effective administration of innovative immuno-oncology therapies in low- and middle-income countries. The ICM initiative is a collaboration between the Clinton Health Access Initiative (CHAI) and the Parker Institute for Cancer Immunotherapy (PICI), along with Bristol Myers Squibb (BMS) and Roche, working with the National Hospital in Abuja, an oncology center in Nigeria recognized for its excellence. Low- and middle-income countries, particularly in sub-Saharan Africa, have historically faced challenges in accessing cancer treatments that have been available in high-income countries for decades. Yet Africa is one of the most affected regions globally, with the number of cancer deaths on the continent expected to double by 20401. Among the various cancers affecting the region, colorectal cancer represents a particular concern and is the focus of this initiative. In Nigeria alone, colorectal cancer accounts for approximately 6.4 percent of all cancers and is responsible for nearly 5,900 deaths a year2 "This demonstration project will show to the world that we have institutions in Nigeria that are ready, with the right investments, to introduce and sustainably provide innovative diagnostics and medications," said Dr. Abubakar Bello, Chief Consultant, Clinical and Radiation Oncologist, National Hospital Abuja and the project's Principal Investigator. "This milestone shows that Nigerian healthcare institutions can deliver world-class cancer care," said Dr. Adekunle Iziaq Salako, Hon. Minister of State for Health and Social Welfare, Nigeria. "This demonstration project will provide critical evidence on how advanced immunotherapy can be integrated into our health system." "This project demonstrates that with the right partnerships and health systems investments, cutting-edge cancer treatments can be delivered with the same operational excellence found anywhere in the world," said Dr. Olufunke Fasawe, CHAI Vice President of Integration and Country Director, Nigeria. Over the next two years, the ICM partnership will support the National Hospital Abuja's demonstration project in Nigeria which features nivolumab, an immunotherapy agent, that is already approved by drug regulators in other countries to address cancers of public health significance. The demonstration project will report on its progress which includes health systems-strengthening investments required to scale up the program. "Immunotherapy is playing a revolutionary role in the fight against cancer," said Sean Parker, Founder and Chairman of PICI. "It's an ethical imperative that access to these lifesaving treatments not be limited to a privileged few. Our goal with ICM is to demonstrate the feasibility of using best-in-class treatments in clinics in low-resource areas and to inspire a bold, multitiered, access-oriented global approach in the fight against cancer. Two decades ago, partners around the world came together to ensure treatment for HIV for millions of people across sub-Saharan Africa. We hope this project inspires a similarly bold, multitiered global approach in the fight against cancer." "At Bristol Myers Squibb, we believe everyone should have the opportunity to benefit from medicines and innovations, regardless of geography or circumstance," said Jasmine Greenamyer, Vice President of Global Purpose and Patient Experience at Bristol Myers Squibb. "Our involvement in the ICM initiative reflects our commitment to co-develop operational excellence and effective administration of innovative immuno-oncology therapies in countries like Nigeria. We are proud to collaborate and accelerate progress for patients and communities." "Where you live should not dictate your health, yet we know millions continue to face obstacles to health care," said Roberto Taboada, Network Lead Anglophone West Africa, Roche Diagnostics, General Manager, Roche Nigeria. "At Roche, we believe that collaboration and cross-sector partnerships are what's needed to increase access to innovation. The ICM partnership is a great example of the public and private sectors each playing a crucial role to spur and scale innovation. We are excited to see the meaningful difference that this brings to patients in Nigeria, and beyond." Notes to editors The ICM initiative brings together nonprofit organizations focused on improving access to high quality healthcare, and two world-class biotechnology companies at the cutting edge of diagnostics and medicines for the treatment of cancer. PICI, BMS, and American Cancer Society (ACS) are providing financial support for the demonstration projects; BMS is donating medication and providing training support; and Roche is donating reagents and providing training support. The initiative builds on CHAI's work to expand access to lifesaving cancer medications through the Cancer Access Partnership (CAP). Since its inception in 2017, CAP has helped increase access to more than two dozen lifesaving cancer medicines in low-income countries in Africa and Asia. About the organizations: The Clinton Health Access Initiative (CHAI) The Parker Institute for Cancer Immunotherapy (PICI) Roche Bristol Myers Squibb (BMS) 1 The Lancet Oncology Commission 2 World Health Organization. International Agency for Research on Cancer. Accessed 10 September 2025. SOURCE Innovative Cancer Medicines WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyClinical Study

100 Deals associated with Nivolumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10316	Nivolumab	L01XC17	DB09035

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Microsatellite instability-high Rectal Cancer	Japan	Ono Pharmaceutical Co., Ltd.	25 Aug 2025
PD-L1 positive Non-Small Cell Lung Cancer	China	Bristol-Myers Squibb Pharma EEIG	22 Jul 2025
Metastatic hepatocellular carcinoma	Australia	Bristol-Myers Squibb Australia Pty Ltd.	26 Jun 2025
Malignant neoplasm of gastro-oesophageal junction	European Union	Bristol-Myers Squibb Pharma EEIG	17 Mar 2025
Malignant neoplasm of gastro-oesophageal junction	Iceland	Bristol-Myers Squibb Pharma EEIG	17 Mar 2025
Malignant neoplasm of gastro-oesophageal junction	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	17 Mar 2025
Malignant neoplasm of gastro-oesophageal junction	Norway	Bristol-Myers Squibb Pharma EEIG	17 Mar 2025
Advanced Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Advanced Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	European Union	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Iceland	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Liechtenstein	Bristol Myers Squibb Co.	08 Mar 2025
Unresectable Hepatocellular Carcinoma	Norway	Bristol Myers Squibb Co.	08 Mar 2025
Carcinoma	Japan	Ono Pharmaceutical Co., Ltd.	09 Feb 2024
Mesothelioma, Malignant	Japan	Ono Pharmaceutical Co., Ltd.	24 Nov 2023
Resectable Lung Non-Small Cell Carcinoma	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jul 2023
Resectable Lung Non-Small Cell Carcinoma	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jul 2023
Resectable Lung Non-Small Cell Carcinoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jul 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mismatch repair-deficient Colonic Cancer	NDA/BLA	China	Bristol-Myers Squibb (China) Investment Co. Ltd.	18 Apr 2024
Mismatch repair-deficient Rectal Cancer	NDA/BLA	China	Bristol-Myers Squibb (China) Investment Co. Ltd.	18 Apr 2024
Advanced Gastric Adenocarcinoma	Phase 3	United States	National Cancer Institute	24 Jun 2024
Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	United States	National Cancer Institute	24 Jun 2024
Metastatic gastric adenocarcinoma	Phase 3	United States	National Cancer Institute	24 Jun 2024
stomach adenocarcinoma	Phase 3	United States	National Cancer Institute	24 Jun 2024
Mediastinal large B-cell lymphoma	Phase 3	United States	National Cancer Institute	05 Oct 2021
Mediastinal large B-cell lymphoma	Phase 3	Australia	National Cancer Institute	05 Oct 2021
Mediastinal large B-cell lymphoma	Phase 3	Canada	National Cancer Institute	05 Oct 2021
Refractory Cancer	Phase 3	United States	Bayer AG	01 Jun 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04879368 (INTEGRATE IIb, ESMO2025)	Phase 3	Malignant neoplasm of gastro-oesophageal junction \| Stomach Cancer	462	Regorafenib+nivolumab	bjemfgpuef(ghqkerwdhm) = bahyxznlrd hbqjaexwne (zrlndrpcpn ) View more	Negative	17 Oct 2025
				Investigator's choice of chemotherapy	bjemfgpuef(ghqkerwdhm) = hdvnicfedf hbqjaexwne (zrlndrpcpn ) View more
NATCH-ICI (ESMO2025)	Phase 3	Non-Small Cell Lung Cancer Neoadjuvant	330	paclitaxel/pemetrexednivolumabcarboplatin + paclitaxel/pemetrexednivolumabcarboplatin + paclitaxel/pemetrexednivolumabcarboplatinpemetrexed	tazrcgdvce(hcgaomejdy) = fmusbkwllw xbeadosssq (iinmqejrqo )	Superior	17 Oct 2025
NCT04050462 (CTgov)	Phase 2	Advanced Hepatocellular Carcinoma	13	Nivolumab 240 mg IV every 2 weeks (Nivolumab Monotherapy)	qkstvpgykn = pfkyxnaxzw ukqltkiauo (iciuxwnrfy, ydcrzotxpa - xddrfwdvum) View more	-	16 Oct 2025
				Nivolumab+BMS-986253 (Nivolumab/BMS-986253 Combination)	qkstvpgykn = xipvpxbnye ukqltkiauo (iciuxwnrfy, bschdmwirk - ixwznndopd) View more
NCT03573947 (OPTIMAL \| TOP1705, CTgov)	Phase 2	metastatic non-small cell lung cancer	46	Ipilimumab+Nivolumab+Paclitaxel	aaxozvlygq(ccyqeosahy) = nonicqjloc uljssbhrgd (lggpyhutcy, dumvutlzcg - yaaapqmosn) View more	-	14 Oct 2025
NCT02408861 (AIDS Malignancy Consortium 095 Study \| AMC 095, CTgov)	Phase 1	AIDS-Related Lymphoma \| Relapsing classical Hodgkin lymphoma \| Lung Cancer ... View more	79	Nivolumab (Dose De-escalation Nivolumab 3 mg/kg (Stratum 1))	hcwczrauqp = bqjgaviham uoceofndpi (tyhlgtxcej, aywalowhiz - vuuviogoxu) View more	-	23 Sep 2025
				Nivolumab (Dose De-escalation Nivolumab 3 mg/kg (Stratum 2))	hcwczrauqp = wicsvrftpa uoceofndpi (tyhlgtxcej, xsoscoqaya - jvemkzhoxu) View more
NCT04396860 (NRG Oncology BN007, Pubmed \| J Clin Oncol)	Phase 2/3	Glioblastoma MGMT-unmethylated	159	Radiotherapy + Immunotherapy (ipilimumab and nivolumab)	jfwfjwlsxx(pypgjppnnt) = hhsqsrkktg ttbjflvmdc (igoalrmppz )	Negative	20 Sep 2025
				Radiotherapy + Temozolomide	jfwfjwlsxx(pypgjppnnt) = jcrtphbscv ttbjflvmdc (igoalrmppz )
NCT04149574 (CheckMate 7G8, CTgov)	Phase 3	Non-Muscle Invasive Bladder Neoplasms	13	BCG+Nivolumab (Arm A)	mjycyoherw = iwuphiartb vffuosffow (amorjpydcn, dkyuleocpi - shlbooooqw) View more	-	16 Sep 2025
				placebo+Nivolumab (Arm B)	mjycyoherw = zydqepyvgk vffuosffow (amorjpydcn, lviwpzettv - axvlxnulhh) View more
NCT03195478 (CheckMate 672, CTgov)	Phase 1/2	Solid tumor \| Relapsed Solid Neoplasm	37	NIVO (Part 1: Arm A)	iejrkppvrz = efoeenndul mejingwjbc (nndqteanmx, iwwqtmjbjq - hoktyddhpa) View more	-	15 Sep 2025
				NIVO (Part 1: Arm B)	iejrkppvrz = vjqelsefce mejingwjbc (nndqteanmx, yphwxoggmz - mwnghhjfnd) View more
NCT03470922 (RELATIVITY-047, Pubmed \| J Immunother Cancer)	Phase 2/3	Melanoma BRAF mutational status \| PD-L1 expression level	714	Nivolumab plus Relatlimab	vsqtqwpncl(keobbvitbw) = ihbfjqfqsq fwqjgzsdnk (vesjcnpytw, 1.0 - 4.9) View more	Positive	12 Sep 2025
				Nivolumab	vsqtqwpncl(keobbvitbw) = llzdgwjdzy fwqjgzsdnk (vesjcnpytw, 2.9) View more
NCT04205552 (NADIM 2, WCLC2025)	Phase 3	Non-Small Cell Lung Cancer Neoadjuvant	86	Nivolumab plus chemotherapy	mebizulmge(cktludgdey) = zxastqbrsz askkgxxfya (drmeglnios )	Positive	09 Sep 2025
				Chemotherapy alone	mebizulmge(cktludgdey) = hwwmefeatm askkgxxfya (drmeglnios )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Nivolumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation